NCT06166589

Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer

The Efficacy and Safety of Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer: A Prospective, Single Arm, Phase II Clinical Study

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 19 (estimated)
• Sponsor: Shanghai Zhongshan Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, single arm, phase II clinical study investigating second-line Zimberelimab and SIROX chemotherapy for patient with previously AG chemotherapy treated pancreatic cancer.

Conditions

• Previously AG Chemotherapy Treated Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	Zimberelimab	Zimberelimab, 240mg, day1. Every 3 weeks as a cycle.
DRUG	Oxaliplatin	Oxaliplatin 60mg/m2, day1、day8. Every 3 weeks as a cycle.
DRUG	S-1	S-1(BSA \< 1.2m2, 40 mg/day; BSA = 1.2\~1.4 m2, 60 mg/day; BSA = 1.4\~1.6 m2, 80 mg/day; BSA \> 1.6 m2, 100 mg/day; bid, day1-14). Every 3 weeks as a cycle.
DRUG	Irinotecan	Irinotecan, 130 mg/m2, day 1, day 8. Every 3 weeks as a cycle.

Timeline

• Start date: 2024-01-01
• Primary completion: 2026-01-01
• Completion: 2027-01-01
• First posted: 2023-12-12
• Last updated: 2023-12-12

Locations

1 site across 1 country: China